Aug 7, 2009
Why Did Pfizer Resort to ‘Michael Clayton’ Tactics at First Neurontin Trial?
Did Pfizer cross the line on the eve of last month’s crucial test trial involving its controversial Neurontin drug? Questions linger about why the world’s largest pharmaceutical company sent a former CIA agent to a whisteblowing scientist’s home the day before he was due to testify. The scientist told The Am Law Litigation Daily he and his family felt intimidated by the investigator’s appearance and are still shaken by the event